Thera-SAbDab

MOXETUMOMAB

>   Structural Summary
TherapeuticMoxetumomab
TargetCD22
Heavy ChainEVQLVESGGGLVKPGGSLKLSCAASGFAFSIYDMSWVRQTPEKCLEWVAYISSGGGTTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARHSGYGTHWGVLFAYWGQGTLVTVSA
Light ChainDIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSILHSGVPSRFSGSGSGTDYSLTISNLEQEDFATYFCQQGNTLPWTFGCGTKLEI
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatFv Fusion
Isotypena
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)NFD
Recorded Developmental TechnologyCAT Phage Display
INN Year Proposed2009
INN Year Recommended2010
Companies InvolvedNational Cancer Institute (USA), AstraZeneca, M. D. Anderson Cancer Center, MedImmune, National Cancer Institute (USA)
Conditions ApprovedHairy cell leukaemia
Conditions Activena
Conditions DiscontinuedChronic lymphocytic leukaemia, Non-Hodgkin's lymphoma, Precursor B-cell lymphoblastic leukaemia-lymphoma, Precursor cell lymphoblastic leukaemia-lymphoma
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]